[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA-Cancer J Clin, 2016, 66:115-132.
[2] 陈万青, 孙可欣, 郑荣寿等. 2014年中国地区恶性肿瘤发病和死亡分析. 中国肿瘤, 2018, 27:1-14.
[3] Feng RM, Zong YN, Cao SM, et al. Curent cancer situation in China: good or bad news from the 2018 global cancer statistics? Cancer Commun, 2019, 39:22.
[4] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版). 中华消化病与影像杂志(电子版), 2020, 10.22-48.
[5] Zeng HM, Chen WQ, Zheng RS, et al.Changing cancer survival in China during 2003-15:a pooled analysis of 17 population-based cancer registries.Lancet Glob Health, 2018, 6:e555-e567.
[6] Zhou J, Sun HC, Wang Z, et al.Guidelines for diagnosis and treatment of primary liver cancer in China(2017 Edition).Liver Cancer, 2018, 7:235-260.
[7] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359:378 -390.
[8] Schulze K, Imbeauds, Letouze E, et al. Exome sequencingof hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet, 2015, 47:505 -511.
[9] Marrera JA, Kudo M, Venook AP, et al. Observational registry of sorafenib use in clinical practice across Child -Pugh subgroups: The GIDEON study. J Hepatol, 2016, 65: 1140 -1147.
[10] Finn RS, Merle P, Granito A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.J Hepatol, 2018, 69:353-358.
[11] Mross K, Frost A, Steinbild S, et a1.A phase I dose-escalationstudy of (BAY 73-4506), aIl inhibitor of oncogenic, angiogenic and stromal kinases, in patients with advanced solid tumors.Clin Cancer Res, 2012, 18:2658-2667.
[12] Bruix J, Qin S, Merle P, et al.Regorafinib for patients with hepatocellular carcinama who progressed on sorafenib on sorafenib treatment(RESORCE):A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2016, 389: 56-66.
[13] Goyal L, Muzumdar MD, Zhu AX. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res, 2013, 19:2310-2318.
[14] Verslype C, Cohn AL, Kelley RK, et a1.Activity of cabozantinib in hepatocellular carcinoma:results from a PhaseⅡrandomized discontinuation tria1(RDT ).Clin Oncol, 2012, 30 : abstract 4007.
[15] Hodi FS, O’Day SJ, McDermott DF, et a1.Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med, 2010;363:711-723.
[16] Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010):a randomised controlled trial. Lancet, 2016, 387: 1540-1550.
[17] Taube JM, Klein A, Brahmer JR, ?et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.Clin Cancer Res, 2014, 20:5064-5074.
[18] El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma: an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, 2017, 89:2492-2502.
[19] Yaut PJ, Finn RS, Cheng AL, et al. CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as firstline (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC ). Ann Oncol, 2019, 30:851-934.
[20] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224 ): a nonrandomised, open-label phase 2 trial. Lancet Oncol, 2018, 19:940-952.
[21] Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab As Second-Line herapy in Patients with Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol, 2020, 38:193-202.
[22] Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol, 2013, 59:81-88.
[23] Richard S, Finn MD, Shukui Qin MD, et al. Atezolizumab plus Bevacizumab in Unresectable epatocellular Carcinoma.N Engl J Med, 2020, 382:1894-1905.
[24] Guardascione M, Toffoli G. Immune checkpoint inhibitors as monotherapy or within a combinatorial strategy in advanced hepatocellular carcinoma. Int J Mol Sci, 2020, 21: e6302.
[25] Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcincma: Current status and prospects. Genes Dis, 2020, 7:359 -369.
[26] Canale M, Ulivi P, Foschi FG, et al. Clinical and circulating biomarkers of survival and recurrence after adiofrequency ablation in patients with hepatocellular carcinoma. Crit Rev Oncol Hematol, 2018, 129 : 44 -53. |
